Transcatheter closure of fenestrations and excluded hepatic veins after fontan: Versatility of the amplatzer device

John W. Moore, Kenneth A Murdison, Gina M. Baffa, Kathy Kashow, John D. Murphy

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: The aim of this study was to evaluate the Amplatzer septal occluder (ASO) for transcatheter closure of fenestrations and excluded hepatic veins in patients after modified Fontan operations. Residual right-to-left shunts have improved surgical results of the Fontan operation. Shunt closure may eventually be desirable to eliminate hypoxemia and reduce risk of embolic complications. Methods and Results: Ten patients with hypoxemia caused by residual shunts after Fontan procedures were evaluated for closure. After favorable results of test occlusion, all shunts were closed with the use of the ASO. Eight ASOs were used to close fenestrations in 7 patients with 6F transvenous sheaths. Three ASOs were used to close excluded hepatic veins in 3 patients with 6F venous sheaths and transbaffle punctures. Fluoroscopy and transesophageal echocardiography were used to guide device placement. Device placement in all patients was successful. All shunts were closed by angiography after device placement. While breathing room air, systemic oxygen saturation rose from 87.9% ± 3.0% to 96.3% ± 0.9% [P < .001) in the patients. There were no complications of the implant procedures and none noted in outpatient follow-up. Conclusions: This experience suggests that the ASO is safe and effective for closing surgical shunts after Fontan procedures. The ASO design allows closure of excluded hepatic veins and has advantages over other devices in closure of fenestrations.

Original languageEnglish (US)
Pages (from-to)534-540
Number of pages7
JournalAmerican Heart Journal
Volume140
Issue number3
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Hepatic Veins
Septal Occluder Device
Fontan Procedure
Equipment and Supplies
Fluoroscopy
Transesophageal Echocardiography
Punctures
Angiography
Respiration
Outpatients
Air
Oxygen

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Transcatheter closure of fenestrations and excluded hepatic veins after fontan : Versatility of the amplatzer device. / Moore, John W.; Murdison, Kenneth A; Baffa, Gina M.; Kashow, Kathy; Murphy, John D.

In: American Heart Journal, Vol. 140, No. 3, 01.01.2000, p. 534-540.

Research output: Contribution to journalArticle

Moore, John W. ; Murdison, Kenneth A ; Baffa, Gina M. ; Kashow, Kathy ; Murphy, John D. / Transcatheter closure of fenestrations and excluded hepatic veins after fontan : Versatility of the amplatzer device. In: American Heart Journal. 2000 ; Vol. 140, No. 3. pp. 534-540.
@article{58035c6456474b9aa12edaa67b516e48,
title = "Transcatheter closure of fenestrations and excluded hepatic veins after fontan: Versatility of the amplatzer device",
abstract = "Background: The aim of this study was to evaluate the Amplatzer septal occluder (ASO) for transcatheter closure of fenestrations and excluded hepatic veins in patients after modified Fontan operations. Residual right-to-left shunts have improved surgical results of the Fontan operation. Shunt closure may eventually be desirable to eliminate hypoxemia and reduce risk of embolic complications. Methods and Results: Ten patients with hypoxemia caused by residual shunts after Fontan procedures were evaluated for closure. After favorable results of test occlusion, all shunts were closed with the use of the ASO. Eight ASOs were used to close fenestrations in 7 patients with 6F transvenous sheaths. Three ASOs were used to close excluded hepatic veins in 3 patients with 6F venous sheaths and transbaffle punctures. Fluoroscopy and transesophageal echocardiography were used to guide device placement. Device placement in all patients was successful. All shunts were closed by angiography after device placement. While breathing room air, systemic oxygen saturation rose from 87.9{\%} ± 3.0{\%} to 96.3{\%} ± 0.9{\%} [P < .001) in the patients. There were no complications of the implant procedures and none noted in outpatient follow-up. Conclusions: This experience suggests that the ASO is safe and effective for closing surgical shunts after Fontan procedures. The ASO design allows closure of excluded hepatic veins and has advantages over other devices in closure of fenestrations.",
author = "Moore, {John W.} and Murdison, {Kenneth A} and Baffa, {Gina M.} and Kathy Kashow and Murphy, {John D.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1067/mhj.2000.108517",
language = "English (US)",
volume = "140",
pages = "534--540",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Transcatheter closure of fenestrations and excluded hepatic veins after fontan

T2 - Versatility of the amplatzer device

AU - Moore, John W.

AU - Murdison, Kenneth A

AU - Baffa, Gina M.

AU - Kashow, Kathy

AU - Murphy, John D.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Background: The aim of this study was to evaluate the Amplatzer septal occluder (ASO) for transcatheter closure of fenestrations and excluded hepatic veins in patients after modified Fontan operations. Residual right-to-left shunts have improved surgical results of the Fontan operation. Shunt closure may eventually be desirable to eliminate hypoxemia and reduce risk of embolic complications. Methods and Results: Ten patients with hypoxemia caused by residual shunts after Fontan procedures were evaluated for closure. After favorable results of test occlusion, all shunts were closed with the use of the ASO. Eight ASOs were used to close fenestrations in 7 patients with 6F transvenous sheaths. Three ASOs were used to close excluded hepatic veins in 3 patients with 6F venous sheaths and transbaffle punctures. Fluoroscopy and transesophageal echocardiography were used to guide device placement. Device placement in all patients was successful. All shunts were closed by angiography after device placement. While breathing room air, systemic oxygen saturation rose from 87.9% ± 3.0% to 96.3% ± 0.9% [P < .001) in the patients. There were no complications of the implant procedures and none noted in outpatient follow-up. Conclusions: This experience suggests that the ASO is safe and effective for closing surgical shunts after Fontan procedures. The ASO design allows closure of excluded hepatic veins and has advantages over other devices in closure of fenestrations.

AB - Background: The aim of this study was to evaluate the Amplatzer septal occluder (ASO) for transcatheter closure of fenestrations and excluded hepatic veins in patients after modified Fontan operations. Residual right-to-left shunts have improved surgical results of the Fontan operation. Shunt closure may eventually be desirable to eliminate hypoxemia and reduce risk of embolic complications. Methods and Results: Ten patients with hypoxemia caused by residual shunts after Fontan procedures were evaluated for closure. After favorable results of test occlusion, all shunts were closed with the use of the ASO. Eight ASOs were used to close fenestrations in 7 patients with 6F transvenous sheaths. Three ASOs were used to close excluded hepatic veins in 3 patients with 6F venous sheaths and transbaffle punctures. Fluoroscopy and transesophageal echocardiography were used to guide device placement. Device placement in all patients was successful. All shunts were closed by angiography after device placement. While breathing room air, systemic oxygen saturation rose from 87.9% ± 3.0% to 96.3% ± 0.9% [P < .001) in the patients. There were no complications of the implant procedures and none noted in outpatient follow-up. Conclusions: This experience suggests that the ASO is safe and effective for closing surgical shunts after Fontan procedures. The ASO design allows closure of excluded hepatic veins and has advantages over other devices in closure of fenestrations.

UR - http://www.scopus.com/inward/record.url?scp=0033835482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033835482&partnerID=8YFLogxK

U2 - 10.1067/mhj.2000.108517

DO - 10.1067/mhj.2000.108517

M3 - Article

C2 - 10966558

AN - SCOPUS:0033835482

VL - 140

SP - 534

EP - 540

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -